Promising combo therapy targets fluid buildup in recurrent ovarian cancer
NCT ID NCT04919629
First seen Apr 09, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control fluid buildup and tumor growth in people whose ovarian, fallopian tube, or peritoneal cancer has returned. About 60 adults with recurrent cancer and persistent fluid in the abdomen or chest will be randomly assigned to one of three treatment groups. The goal is to see if the combinations are safer and more effective than bevacizumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.